Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172781 | 0.79 | MAPT (0.45) | ALDH1A1PKMALOX5MAPTLMNA | |
| SCHEMBL10642296 | 0.78 | TRPV4 (0.45) | ALDH1A1SMN1; SMN2LMNATRPV4KMT2A | |
| SCHEMBL8646151 | 0.78 | TRPV4 (0.45) | ALDH1A1SMN1; SMN2TRPV4KMT2AMAPK1 | |
| SCHEMBL29469795 | 0.76 | RXRA (0.51) | ALDH1A1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL4944543 | 0.75 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2TRPV4KMT2A | |
| SCHEMBL31172768 | 0.74 | TACR1 (0.37) | ALDH1A1SMN1; SMN2ALOX5MAPTSMPD1 | |
| SCHEMBL8646152 | 0.73 | CNR2 (0.53) | TRPV4 | |
| SCHEMBL1036692 | 0.72 | ALPL (0.52) | ALDH1A1SMN1; SMN2MAPTTRPV4KMT2A | |
| SCHEMBL31525522 | 0.72 | TRPV4 (0.47) | ALDH1A1SMN1; SMN2PKMMAPTTRPV4 | |
| SCHEMBL10851488 | 0.72 | KDM4E (0.45) | ALDH1A1SMN1; SMN2HDAC8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2024189598-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | ALDH1A1 2242/4885SMN1; SMN2 1852/4885PKM 2293/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | ALDH1A1 2242/4885SMN1; SMN2 1852/4885PKM 2293/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | ALDH1A1 1068/4885SMN1; SMN2 3098/4885PKM 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.